Vista Oncology Inc., PS

Olympia, Washington 98506

1 studies enrolling now · 13 studies all time

What they study most

Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent, Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 3b, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hodgkin Lymphoma, Leukemia, Myeloid, Acute, MPN (Myeloproliferative Neoplasms), Marginal Zone Lymphoma, Multiple Myeloma

Studies at this site

• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) — Recruiting now
• Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) — Completed
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Running, not enrolling
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma — Stopped early
• Connect® Myeloid Disease Registry — Stopped early
• Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma — Running, not enrolling
• A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis — Stopped early
• Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Completed
• A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer — Completed
• A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer — Completed
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) — Completed
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients — Completed
• Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma — Stopped early